AI MARKET SCANNING

Protagonist Therapeutics, Inc.

📅 Next Catalyst: Nov 05, 2026 (🌙 Close) 🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +2.06%
MAX GAP RECORD +5.60%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $PTGX
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 05, 2026 Earnings Release 2026-11-05 (AFTER CLOSE (21:00)) 🔮 UPCOMING 🔒
Aug 05, 2026 Earnings Release 2026-08-05 (AFTER CLOSE)
+5.60%
May 05, 2026 Earnings Release 2026-05-05 (AFTER CLOSE)
+3.82%
Feb 25, 2026 Earnings Release 2026-02-25 (AFTER CLOSE)
+0.46%
Nov 06, 2025 Earnings Release 2025-11-06 (AFTER CLOSE)
+0.43%
Aug 06, 2025 Earnings Release 2025-08-06 (AFTER CLOSE)
+0.47%
May 06, 2025 Earnings Release 2025-05-06 (AFTER CLOSE)
-0.57%
Feb 21, 2025 Earnings Release 2025-02-21 (BEFORE OPEN)
+2.88%

VOLATILITY & GAP BIAS

AVG GAP MOVE 2.2%
Bullish Gaps (8)
Bearish Gaps (0)
Neutral / Flat (6)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $PTGX

EXECUTIONS1 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
2026-10-30 🔒 PRO RADAR ••• x• $•••.•• → $•••.•• 65m +1.68%
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Protagonist Therapeutics, Inc. operates as a discovery and development company in the United States. It develops Icotyde, a first-in-class investigational targeted oral peptide for the treatment of adults and pediatric patients 12 years of age and older with moderate-to-severe plaque psoriasis; and Rusfertide, a first-in-class investigational injectable mimetic of the…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗